Ledger.Open graph →
SEC Form D · Amendment · filed November 12, 2021

Elicio Therapeutics, Inc

Offering
$15.0M
Sold
$14.5M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
CAMBRIDGE, MA
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (27)

David Boyle · Chicago, ILDirectorChris Eng · Austin, TXDirectorTrey Conkling · Austin, TXExecSandy Modell · Orlando, FLDirectorGrayBul Tyde GP LLC · Greenville, SCDirectorRobert Ruffolo · Cambridge, MADirectorJamie L. Shiller · Dover, DEDirectorTaylor Davis · Greenville, SCDirectorJobst T. Klemme · New York, NYDirectorJulian Adams · Cambridge, MADirectorDaniel Geffken · Cambridge, MAExec · DirectorGraycliff Capital Partners LLC · Greenville, SCExecOfer Gonen · Cambridge, MADirectorAnnette Matthies · Cambridge, MAExecChristopher Haqq · Cambridge, MAExecRobert Connelly · Cambridge, MAExec · DirectorSamon Suwannarat · Grand Cayman, Cayman IslandsExec · DirectorDonald Retreage, Jr · Euclid, OHDirectorJason Burke · Dover, DEExec · DirectorDaphne Karydas · Cambridge, MADirectorSohail Hassan · Houston, TXExecRosemarie H. Fanelli · New York, NYExec · DirectorFeng H. Xiao · New York, NYExec · DirectorDavid Keane · COLUMBUS, OHDirectorCarol Ashe · Cambridge, MADirectorVladimir Ghidirim · Dover, DEExecChristopher Abele · Madison, WIDirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗